RSS Feeds
Search

In-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..9 of 9 - per page
Order by
New Chemical Entities and innovative therapeutic targets
NCEs for innovative therapeutic targets in inflammatory/immunologic diseases. More
UK Marketing Partner
Are you a small to medium company seeking a UK presence? More
Acquisition of UK Hospital established brands
UK partner for strategic divestments More
Acquisition of UK Primary Care ethical brands
Strategic divestments of primary care sales focussed brands More
Injectables and oral medicines for hospital use
In-licensing injectables andoral medicines for the hospital market, originals for orphan/nichemarkets More
Seeking partners who want to divest well-established products in any therapeutic area.
If you are considering divesting one or more brands or the whole portfolio in any therapeutic or geographic area, please contact DESMA PHARMA Group for a preliminary assessment More
Sales and Marketing of innovative Rx/OTC products in Russia/CIS
Invar is a Russian based pharmaceutical company with proven sales and marketing capabilities around the local area. Partner with Invar to promote your products into and around Russia. More
Seeking to in-license late stage prescription products into the Nordic region
Phase III and beyond prescription products are sought to in-license into the four major Nordic countries. More
Prescription bound chemical substances (NCEs) OR new value added prescription products to in-license for the Nordic market
Leiras Finland is looking to in-license new prescription products for the Nordic region including Finland, Sweden, Norway and Denmark. More
Displaying 1..9 of 9 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Cardiovascular Biomarkers: Players, products and prospects (Volume III)
Aug 2008 - 120 pages - $1,040
CV & Diabetes Market Forecast
Jan 2009 - $15,200
Who's Developing What in Cardiovascular Devices?
Sep 2010 - 412 pages - $1,040
Stem Cell Therapy Holds Promise for Ischemic Heart Disease Patients
Nov 2010 - 7 pages - $500
Cardiovascular and metabolic market overview forecast model
Jan 2010 - $15,200
CardioVascular BioTherapeutics, Inc. – Product Pipeline Review – Q1 2011
May 2011 - 43 pages - $500
CardioVascular BioTherapeutics, Inc. - Product Pipeline Review - Q4 2010
Nov 2010 - 40 pages - $500
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects
Aug 2008 - 352 pages - $2,615
Osaka Medical Center for Cancer and Cardiovascular Diseases – Developmental Therapeutics Review – Q4 2010
Dec 2010 - 36 pages - $500
CardioVascular BioTherapeutics, Inc. (CVBT) - Strategic SWOT Analysis Review
May 2011 - 23 pages - $125
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us